Market Overview

Avicanna to Host Virtual Symposium Titled "Medical Cannabis 2.0" on July 21st, 2020 in Partnership with Medical Cannabis By Shoppers™ in Anticipation of the Launch of its Rho Phyto™ Product Line

Share:

- - -
The symposium will present the evolution of medical cannabis including the Avicanna-led advancements in R&D for novel cannabinoid delivery forms and formulations in addition to enhanced access for patients by Medical Cannabis by Shoppers.

- - -

This year's annual symposium coincides with the expected launch of Avicanna's RHO Phyto advanced medical cannabis products and In the wake of COVID-19, a virtual format will be used that allows for a broader reach to global patients and the medical community.
- - -
  Leading experts in R&D and clinical development will discuss the potential therapeutic benefits of medical cannabis to address the importance of working with healthcare practitioners for safe and effective dosing. 

- - -

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTO, June 22, 2020 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that on July 21st, 2020 it will be hosting a virtual symposium titled "Medical Cannabis 2.0" in partnership with Medical Cannabis by Shoppers. Patients and health care practitioners globally can join the virtual symposium to learn more about the potential advantages of medical cannabis and the advancement of product offerings including Avicanna's RHO Phyto product offerings and advanced cannabinoid research collaboration at the University of Toronto. In addition, experts will discuss the pharmacology, safety, and dosing guidelines of medical cannabis for therapeutic conditions.  This includes presentations on the, efficacy of cannabinoids for chronic pain, anxiety, depression, and other comorbidities as well as an overview of the patient pathway to Medical Cannabis by Shoppers.

"In this unprecedent time, where patients and practitioners have many questions and are seeking alternative and natural solutions, we are pleased to welcome you all to our virtual symposium on medical cannabis. My talk on Common Medical Comorbidities will discuss how medical cannabis can be used for the management of clinical conditions that have common associated comorbidities of anxiety, depression and appetite and sleep disorders. Alongside my colleagues and collaborators, we hope you will find value in all our presentations and that they will provide important information, as patients and health care practitioners seeking to learn more about medical cannabis." – Dr. Amza Ali, Chief Medical Officer of Avicanna

Discussions will be led by clinicians and scientists from the Avicanna team as well as from prestigious Canadian academic and clinical research organizations including the University of Toronto and University Health Network's Toronto General Hospital.

The agenda for the virtual symposium is as follows:

  • An Introduction to Cannabinoids and Their Pharmacology – Dr. Ruth Ross (Professor and Chair, Department of Pharmacology & Toxicology, Faculty of Medicine, University of Toronto, Senior Scientist, Campbell Family Mental Health Research Institute, CAMH)
  • Advanced Cannabinoid Research and drug development at the University of Toronto – Dr. Pauric Bannigan (Post-Doctoral Fellow from Dr Christine Allen's laboratory at the Leslie Dan Faculty of Pharmacy, University of Toronto)
  • Medical Cannabis 2.0 and Avicanna's RHO Phyto product offerings– Dr. Justin Grant (Executive Vice President of Scientific Affairs, Avicanna)
  • The Potential of Cannabinoids for Chronic Pain – Dr. Hance Clarke (Staff Anesthesiologist
    Director Pain Services, Director Good Hope Ehlers Danlos Clinic, Medical Director of The Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Associate Professor, Department of Anesthesia, University of Toronto)
  • Anxiety, Depression and Other Comorbidities in Patients to be Treated with Cannabinoids: Implications for Optimal Care – Dr. Amza Ali (Chief Medical Officer, Avicanna)
  • An Introduction to Medical Cannabis by Shoppers Drug Mart – Neil D'Souza (Senior Manager, Operations, Medical Cannabis by Shoppers Drug Mart)
  • The Future of Medical Cannabis Panel Discussion– (Aras Azadian, CEO of Avicanna Inc. / Pat McCutcheon, CEO MediPharm Labs / Kaveh Kahen, CEO of Sigma Analytics)

To register for the virtual symposium please visit: www.avicanna.com/symposium.

About Avicanna Inc.

Avicanna is an Ontario, Canada based corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and includes statements with respect to the ability of the Company to successfully host a virtual symposium. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 15, 2020, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE Avicanna Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2020/22/c4805.html

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com